ClinicalTrials.gg
CompletedNCT00348296Updated Jul 30, 2010

Efficacy and Safety Study of GB-0998 for Treatment of Systemic Sclerosis

A Phase 3 interventional study of High-dose intravenous immunoglobulin (Venoglobulin-IH) in Scleroderma, Systemic, sponsored by Benesis Corporation. Completed at 1 site in Japan. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2010-07-30.

Sponsored by Benesis Corporation · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 18 studies in Scleroderma, Systemic with a site in Japan — 4 open to participants now, 6 under way, 6 of them phase 3. Scleroderma, Systemic · Japan.

Planned enrollment
13th of 18
60 · median 111
Started
2006
the only one that year
Phase 3
9 of 18
3 open now
Registered
1st of 18
by date
Lead sponsor
1 of 18
Benesis Corporation

Among the 18 studies in Scleroderma, Systemic with a site in Japan, this one is the 13th largest by planned enrollment, is the only one that started in 2006, is one of 9 in phase 3, and was the 1st registered.

Scleroderma, Systemic

614 studies on the registry are indexed under Scleroderma, Systemic; 222 are open to participants now.

Browse Scleroderma, Systemic studies →

Open to participants now

4 of the 18 studies in Scleroderma, Systemic with a site in Japan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 146 Scleroderma, Systemic studies recruiting now, 84 (58%) set no upper age limit and 49 (34%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Scleroderma, Systemic with a site in Japan, or all of them as a file.
02

Study summary

This randomized, double-blind, placebo-controlled multi-center study will carry out to assess the efficacy of GB-0998 in the treatment of the systemic sclerosis based on the changes in modified Rodnan total skin thickness score (TSS) as primary endopoint, and in addition, to assess the safety of GB-0998.

03

Conditions studied

  • Scleroderma, Systemic

Browse trials for

Keywords

  • Scleroderma, Systemic
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who have sclerosis located proximal to the elbow joint with diffused systemic scleroderma.
  • Patients who have not less than 20 points of TSS.
  • Patients with no appropriate therapeutic treatment.

Exclusion criteria

Exclusion Criteria:

  • Patients with severe hepatic disorder, severe renal disorder or severe heart disorder.
  • Patients with malignant tumors.
  • Patients who have the anamnesis of shock or to this drug.
  • Patients who have the anamnesis of cerebral infarction or symptom of these diseases.
  • Patients who have been diagnosed as IgA deficiency in their past history.
  • Pregnant, lactating, and probably pregnant patients, and patients who want to become pregnant.
  • Patients who had any dose increase or new dosing of within 12 weeks before consent.
  • Patients who were administered other drug within 12 weeks before consent.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
60 participants (estimated)

Interventions

06

What researchers measure

Primary outcomes

  1. Changes in TSS at 12 weeks

Secondary outcomes

  1. Changes in joint motion, oral aperture, active hand spread, fingertip-to-palm distance, health assessment questionnaire, histological analysis of dermal section at 12 weeks.; Adverse events and laboratory test.

07

Study locations

1 site
  • Nagasaki University
    Nagasaki, 852-8501, Japan
08

References and documents

Publications

  • Takehara K, Ihn H, Sato S. A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):151-6. Epub 2013 Jul 23. PubMed 23910617 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2006, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 3, 2006
First posted
Jul 4, 2006
Start
Jul 2006
Primary completionActual
Jul 2009
CompletionActual
Jul 2009
Last update
Jul 30, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00348296
Lead sponsor
Benesis Corporation
First posted
Jul 4, 2006
Start date
Jul 2006
Primary completion
Jul 2009
Completion
Jul 2009
Last update
Jul 30, 2010

Study contacts

Kazuhiko Takehara, Professor
study chair · Kanazawa University
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion